TL;DR
This paper outlines the protocol for the VITaCCA trial, a randomized, double-blind, placebo-controlled study investigating whether early high-dose intravenous vitamin C can reduce organ failure in patients who have suffered a cardiac arrest. The study aims to address the significant organ damage that occurs during the reperfusion phase after circulation is restored, a critical unmet need in post-cardiac arrest care.
What Problem Does This Paper Address?
Cardiac arrest is a life-threatening event where the heart suddenly stops beating. Even when circulation is successfully restored (Return of Spontaneous Circulation - ROSC), a cascade of damaging processes, known as ischemia/reperfusion injury, occurs. This injury is driven by the massive release of reactive oxygen species (ROS), which can lead to widespread organ damage and contribute to poor outcomes. Current treatments, like targeted temperature management, help but don't fully mitigate this injury. Vitamin C is a potent antioxidant that can scavenge ROS and reduce their production. However, vitamin C levels are rapidly depleted in critically ill patients, and oral supplementation is insufficient. This study aims to determine if early, high-dose intravenous vitamin C can effectively reduce organ failure in the crucial period following cardiac arrest.
Methods
The VITaCCA trial is a multi-center, randomized, double-blind, placebo-controlled study with a three-arm design. A total of 270 adult patients who have experienced an out-of-hospital cardiac arrest and achieved ROSC will be recruited from seven intensive care units in the Netherlands. Patients will be randomly assigned to one of three groups:
- Placebo: Infusion of 0.9% NaCl.
- Supplementary Dose: 3 grams of vitamin C per day.
- Pharmacological Dose: 10 grams of vitamin C per day.
These infusions will be administered intravenously every 12 hours for a total of 96 hours (4 days). The first dose is intended to be given within 5 hours of ROSC. All patients will also receive intravenous thiamine (200 mg every 12 hours for 4 days) to limit oxalate production.
The primary endpoint is the change in the Resuscitation-Sequential Organ Failure Assessment (R-SOFA) score from baseline to 96 hours. Secondary endpoints include neurological outcomes, mortality, length of ICU and hospital stay, myocardial injury, vasopressor support, lung injury, and various other clinical and biochemical markers.
Datasets
Not discussed in the paper. This paper describes a study protocol, not a completed study with datasets.
Key Insights and Ideas
- Vitamin C Depletion: The paper highlights that vitamin C stores are rapidly exhausted in critically ill patients after cardiac arrest, necessitating intravenous administration for effective replenishment.
- Targeted Intervention: The study focuses on the early post-cardiac arrest period, recognizing that ischemia/reperfusion injury is a major contributor to poor outcomes and that interventions during this window are crucial.
- Dose-Finding Approach: By including both a "supplementary" (3g) and a "pharmacological" (10g) dose, the study aims to explore potential dose-dependent effects of vitamin C, addressing the uncertainty around optimal dosing.
- R-SOFA as Primary Endpoint: The use of an adjusted SOFA score (R-SOFA) specifically designed for post-cardiac arrest patients is a novel approach to better capture the effects of the intervention on organ dysfunction in this context.
Key Results
Not discussed in the paper. This paper is a study protocol and does not present results from the trial.
Limitations and Future Work
- Degradation Products: The authors note that an initial plan to use commercially prepared study medication was abandoned due to the formation of unknown degradation products in polypropylene vials. This led to a decision to prepare the study medication fresh, and a separate study is underway to identify and quantify these degradation products.
- Sample Size for Mortality: While the study is powered to detect a clinically meaningful effect on organ failure (2.0 SOFA points), the authors mention that achieving a similar power for mortality as a primary outcome would require a much larger sample size (3000 patients).
- Future Directions: If the study demonstrates that early high-dose vitamin C is effective, it could be considered a novel treatment for post-cardiac arrest patients. Further research may focus on optimizing dosing, duration, and identifying specific patient subgroups who might benefit most. The ongoing study on vitamin C degradation products will also be important for future clinical applications.
Summary updated